Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Zinke

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|January 19, 2018
Catharina Klausenitz, Andreas Zinke, Jens Peter Kühn
Journal for Immunotherapy of Cancer|May 17, 2020
Nivolumab and dinutuximab beta in two patients with refractory neuroblastomaKaroline Ehlert, Ina Hansjuergens, Andreas Zinke, et al.
Mabs|November 10, 2017
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHOIna Mueller, Karoline Ehlert, Stefanie Endres, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|January 19, 2018
Catharina Klausenitz, Andreas Zinke, Jens Peter Kühn
Journal for Immunotherapy of Cancer|May 17, 2020
Nivolumab and dinutuximab beta in two patients with refractory neuroblastomaKaroline Ehlert, Ina Hansjuergens, Andreas Zinke, et al.
Mabs|November 10, 2017
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHOIna Mueller, Karoline Ehlert, Stefanie Endres, et al.
Pageof 1